The U.S. Food and Drug Administration has issued an EUA for the emergency use of GOHIBIC for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).
GOHIBIC has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving IMV, or ECMO.
The emergency use of GOHIBIC is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.
To order Gohibic, inpatient hospitals can call ASD at 1-800-746-6273 or email service@asdhealthcare.com or login into their ASD portal and place an order.
To download a copy of the GOHIBIC Hospital Formulary P&T Kit click here
To receive copies of the GOHIBIC Frequently Asked Questions and AMCP Dossier, email your name, NPI number and state of licensure to info.gohibic@inflarx.com.
